药物在实际应用中的风险和益处:。

Mitchell H Katz
{"title":"药物在实际应用中的风险和益处:。","authors":"Mitchell H Katz","doi":"10.1001/2013.jamainternmed.868","DOIUrl":null,"url":null,"abstract":"Risks and Benefits of Medications in Real-World Practice A ll drugs have adverse effects. The challenge for practicing physicians is to determine which medications have the fewest adverse effects for a given therapeutic benefit. Unfortunately, drugs with similar indications often have not been directly compared with one another because their approvals were based on comparison with placebo or with only one member of the same or a similar class. Moreover, the comparable risks for unusual adverse effects with a group of different medications having similar indications can be even more challenging because most phase 3 efficacy trials are not powered to accurately estimate or even detect the incidence of unusual occurrences. As editors, we were particularly happy to see this article by Toh et al for its content and for its methods. Drugs acting on the renin-angiotensin-aldosterone system are increasingly in use. Angioedema is an uncommon adverse effect that can be life-threatening. Using the Food and Drug Administration’s Mini-Sentinel program, Toh et al show that all the drugs acting on this system are not associated with the same incidence of angioedema. Specifically, the incidence was significantly higher for angiotensin-converting enzyme inhibitors and aliskiren than for angiotensin receptor blockers, and all the study drugs were associated with a greater incidence of angioedema compared with the reference category of -blockers. Beyond the content, we commend the Food and Drug Administration for developing the Mini-Sentinel Distributed Database; this analysis draws on medication use and disease diagnoses from 17 health plans. We believe that careful postmarketing surveillance, like this project, is essential for us to learn the risks and benefits of medications in real-world practice.","PeriodicalId":8290,"journal":{"name":"Archives of internal medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2012-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/2013.jamainternmed.868","citationCount":"0","resultStr":"{\"title\":\"Risks and benefits of medications in real-world practice:.\",\"authors\":\"Mitchell H Katz\",\"doi\":\"10.1001/2013.jamainternmed.868\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Risks and Benefits of Medications in Real-World Practice A ll drugs have adverse effects. The challenge for practicing physicians is to determine which medications have the fewest adverse effects for a given therapeutic benefit. Unfortunately, drugs with similar indications often have not been directly compared with one another because their approvals were based on comparison with placebo or with only one member of the same or a similar class. Moreover, the comparable risks for unusual adverse effects with a group of different medications having similar indications can be even more challenging because most phase 3 efficacy trials are not powered to accurately estimate or even detect the incidence of unusual occurrences. As editors, we were particularly happy to see this article by Toh et al for its content and for its methods. Drugs acting on the renin-angiotensin-aldosterone system are increasingly in use. Angioedema is an uncommon adverse effect that can be life-threatening. Using the Food and Drug Administration’s Mini-Sentinel program, Toh et al show that all the drugs acting on this system are not associated with the same incidence of angioedema. Specifically, the incidence was significantly higher for angiotensin-converting enzyme inhibitors and aliskiren than for angiotensin receptor blockers, and all the study drugs were associated with a greater incidence of angioedema compared with the reference category of -blockers. Beyond the content, we commend the Food and Drug Administration for developing the Mini-Sentinel Distributed Database; this analysis draws on medication use and disease diagnoses from 17 health plans. We believe that careful postmarketing surveillance, like this project, is essential for us to learn the risks and benefits of medications in real-world practice.\",\"PeriodicalId\":8290,\"journal\":{\"name\":\"Archives of internal medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-11-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1001/2013.jamainternmed.868\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of internal medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1001/2013.jamainternmed.868\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of internal medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1001/2013.jamainternmed.868","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
Risks and benefits of medications in real-world practice:.
Risks and Benefits of Medications in Real-World Practice A ll drugs have adverse effects. The challenge for practicing physicians is to determine which medications have the fewest adverse effects for a given therapeutic benefit. Unfortunately, drugs with similar indications often have not been directly compared with one another because their approvals were based on comparison with placebo or with only one member of the same or a similar class. Moreover, the comparable risks for unusual adverse effects with a group of different medications having similar indications can be even more challenging because most phase 3 efficacy trials are not powered to accurately estimate or even detect the incidence of unusual occurrences. As editors, we were particularly happy to see this article by Toh et al for its content and for its methods. Drugs acting on the renin-angiotensin-aldosterone system are increasingly in use. Angioedema is an uncommon adverse effect that can be life-threatening. Using the Food and Drug Administration’s Mini-Sentinel program, Toh et al show that all the drugs acting on this system are not associated with the same incidence of angioedema. Specifically, the incidence was significantly higher for angiotensin-converting enzyme inhibitors and aliskiren than for angiotensin receptor blockers, and all the study drugs were associated with a greater incidence of angioedema compared with the reference category of -blockers. Beyond the content, we commend the Food and Drug Administration for developing the Mini-Sentinel Distributed Database; this analysis draws on medication use and disease diagnoses from 17 health plans. We believe that careful postmarketing surveillance, like this project, is essential for us to learn the risks and benefits of medications in real-world practice.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Archives of internal medicine
Archives of internal medicine 医学-医学:内科
自引率
0.00%
发文量
1
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信